KUALA LUMPUR: The United States (US) pharmaceutical companies are likely to see increased sales in Malaysia following the signing of the Malaysia-US Agreement on Reciprocal Trade (ART).
In a statement today, BMI Country Risk & Industry Research (BMI), a unit of Fitch Solutions Group Ltd, said the trade agreement will streamline market access for US pharmaceuticals and medical devices in Malaysia by reducing regulatory barriers.
